Key Highlights

  • Regeneron (NASDAQ:REGN) gained 0.58% to USD 957.76 on November 17, among the few stocks higher that day, and remains about 3.4% under its 52-week high.
  • Revenue for the third quarter reached USD 5.116 billion, up 36%, while non-GAAP EPS surged 70% to USD 20.07 from USD 11.83.
  • Sanofi sales of Dupixent rose to about USD 6.5 billion, up 35%, while EYLEA HD advanced 62% to USD 699 million and Libtayo grew 51% to USD 550 million.
  • On November 17 the European Commission endorsed alternative Libtayo dosing, and the widened Sanofi Partnership brings in USD 1.0 billion upfront.

Record Sales Spread Across the Portfolio

Regeneron released third quarter figures on October 30. Total revenues stood at USD 5.116 billion, versus USD 3.754 billion, GAAP diluted EPS reached USD 18.45 against USD 13.62, and non-GAAP EPS hit USD 20.07. Sanofi, which reports Dupixent, recorded sales that grew 35% to around USD 6.5 billion, while Sanofi collaboration Revenue jumped 68% to USD 2.724 billion. Across eye care, United States EYLEA HD sales increased 62% to USD 699 million, and the legacy EYLEA declined 41% to USD 400 million, so the combined Franchise slipped only 1% to USD 1.099 billion. Libtayo revenue advanced 51% to USD 550 million, with U.S. revenue up 81%. Praluent went up 21% to USD 81 million, and Evkeeza climbed 28% to USD 55 million. Chief executive Leonard S. Schleifer stated that Dupixent, EYLEA HD and Libtayo each set record net sales. GAAP Net Income grew 33% to USD 1.949 billion, while non-GAAP net income surged 67% to USD 2.15 billion. Lynozyfic jumped from USD 1 million to USD 19 million, and Bayer collaboration revenue dropped 23% to USD 267 million.

Guidance Revisions and Shareholder Payouts

The 2026 non-GAAP product gross Margin outlook was raised to roughly 86%, up from 84% to 85%. Non-GAAP selling, general and administrative guidance was reduced to USD 2.4 billion to USD 2.5 billion, versus USD 2.5 billion to USD 2.6 billion previously, and Research and Development guidance edged higher to USD 6.05 billion to USD 6.15 billion. Over the first nine months the company repurchased USD 2.3 billion of stock, leaving around USD 2.2 billion of authorization, and it holds approximately USD 18.9 billion of cash and marketable securities. The widened Sanofi pact supplies USD 1.0 billion upfront, booked in the fourth quarter, plus as much as USD 7.0 billion in milestones, and development and commercialization costs are split evenly. Long Term Debt sits near USD 2.0 billion, compared with cash and securities of USD 18.9 billion.

Pipeline and Regulatory Milestones

The European Commission signed off on Libtayo dosing of 700 milligrams every six weeks across six cancer indications on November 17. Phase 2 baloncibart results in postural tachycardia syndrome were shared November 12, showing a nominal drop of 11.4 beats per minute against placebo, with a Phase 3 trial slated for the first half of 2027. Early siRNA findings in fatty liver disease, released November 8, showed liver fat falling between 58% and 80%. An extended government arrangement for Inmazeb, valued near USD 270 million, and an FDA decision target in February 2027 for the Ordspono resubmission also stand out. Shares rose 0.58% on Tuesday, and a relative strength reading near 68 signals constructive momentum. In October the company presented ten abstracts at a major oncology meeting and reported zero new heterotopic ossification lesions compared with nine on placebo in an extension of the Pasatru study. Longer term Libtayo data showed a hazard ratio for death of 0.63 that did not achieve statistical significance. Investor conferences are set for December 1 and December 2.

Where Things Stand

Regeneron is expanding across its core franchises and has taken on a larger Sanofi partnership. Upcoming regulatory decisions and the 2027 outlook will shape whether the stock can reach new highs, and Canadian investors will focus on the same pipeline catalysts.